Navigation Links
Amyloid Beta Level in Serum Predicts Risk for Vascular Disease in First-Degree Relatives of Alzheimer's Patients
Date:2/6/2009

People with a family history of Alzheimer’s disease, who have high levels of amyloid beta (A) in the serum, are at increased risk for vascular disease.

Manhasset, NY (Vocus) February 6, 2009 -- People with a family history of Alzheimer’s disease, who have high levels of amyloid beta (A²) in the serum, are at increased risk for vascular disease. These heightened A² levels may predict whether those without symptoms may progress towards dementia in years to come.

Michael Mullan, MD, and his colleagues at the Roskamp Institute in Sarasota, Fl., collaborated with statisticians at the London School of Hygiene and Tropical Medicine to see if elevated levels of A² in the blood in first-degree relatives of Alzheimer’s patients are associated with risk factors for vascular disease. Recent studies have shown that vascular disease is a major risk factor for Alzheimer’s. They recruited 197 local study subjects from the Alzheimer’s Disease Anti-Inflammatory Prevention Trial, which included unaffected family members, as well as 98 community elders in Florida. They studied the association of amyloid beta levels in serum with risk factors for vascular disease, including total cholesterol, LDL, HDL, systolic blood pressure, diastolic blood pressure and serum creatinine. They also looked at medications prescribed for vascular disease or the risk factors associated with vascular disease.

A² in serum is used as a marker to predict A² accumulation in the brain, which is one of the key pathologies of Alzheimer’s. In this study, the scientists found A² levels were significantly higher in first-degree relatives of Alzheimer’s patients, as compared with the elder community controls. The scientists say they suspect this elevation may be “indicative of increased amyloid beta production due to genetic and/or other risk factors.”

“These findings suggest that an increased risk of Alzheimer’s disease associated with family history may be mediated in part through the enrichment of individuals with vascular risk factors and may be reflective of pre-symptomatic Alzheimer’s disease pathology,” Dr. Mullan and his colleagues wrote.

In another stunning finding in the same issue of Molecular Medicine, scientists from Virginia Commonwealth University, Northwestern University, UCSF, UCLA, University of Pennsylvania, and University of North Carolina, identified a genetic signature for a hepatitis C virus-induced liver cancer, and different genetic handprints for cirrhosis caused by hepatitis C. They were able to use these genetic signatures to distinguish between pathological stages of liver cancer and early disease states, suggesting a way to diagnose this hepatocellular carcinoma earlier in the disease process.

Molecular Medicine is published by The Feinstein Institute for Medical Research, part of the North Shore-LIJ Health System. For more information on the study, visit www.molmed.org or contact Veronica J. Davis. Free podcasts from the latest issue of Molecular Medicine are also available on the journal’s web site and in iTunes.

###

Read the full story at http://www.prweb.com/releases/2009/02/prweb1966994.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis
2. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
3. MSU study finds high level of medical mistrust among minority women impacts quality of health care
4. Ther-Rx Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
5. ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
6. New Web-Based User Self Service & Identity Management Software for Active Directory takes Security, User Convenience to a Whole New Level
7. Mammography utilization in the United States decreases: A state-level look
8. HPV18 DNA levels are not prognostic for precancerous cervical lesions
9. Cleveland Clinic and Mubadala Healthcare Name CEO of Cleveland Clinic Abu Dhabi
10. New Study: Higher DHA Levels Improve Neurodevelopmental Outcomes in Premature Girls
11. Children with inflammatory bowel disease have surprisingly high folate levels, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... San Diego, CA (PRWEB) , ... June 24, 2016 , ... ... up with the American Cancer Society and the Road To Recovery® program to drive ... care to seniors and other adults to ensure the highest quality of life and ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
Breaking Medicine Technology: